A Review of the Pharmacokinetics of Abacavir

@article{Yuen2008ARO,
  title={A Review of the Pharmacokinetics of Abacavir},
  author={G. Yuen and S. Weller and G. Pakes},
  journal={Clinical Pharmacokinetics},
  year={2008},
  volume={47},
  pages={351-371}
}
  • G. Yuen, S. Weller, G. Pakes
  • Published 2008
  • Medicine
  • Clinical Pharmacokinetics
  • Abacavir is a carbocyclic 2′-deoxyguanosine nucleoside reverse transcriptase inhibitor that is used as either a 600-mg once-daily or 300-mg twice-daily regimen exclusively in the treatment of HIV infection. Abacavir is rapidly absorbed after oral administration, with peak concentrations occurring 0.63–1 hour after dosing. The absolute bioavailability of abacavir is approximately 83%. Abacavir pharmacokinetics are linear and doseproportional over the range of 300–1200 mg/day. To date, one study… CONTINUE READING
    102 Citations

    Paper Mentions

    Blog Post
    PharmGKB summary: abacavir pathway
    • 4
    The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women
    • 6

    References

    SHOWING 1-10 OF 88 REFERENCES
    Methadone Blood Concentrations Are Decreased by the Administration of Abacavir Plus Amprenavir
    • 54
    Pharmacodynamics of Abacavir in an In Vitro Hollow-Fiber Model System
    • 32
    • PDF